Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects
Clin Drug Investig
.
2019 May;39(5):453-454.
doi: 10.1007/s40261-019-00777-6.
Authors
Rebecca E Wrishko
1
,
Jacqueline B McCrea
2
,
Ka Lai Yee
1
,
Wen Liu
1
,
Deborah Panebianco
1
,
Eric Mangin
1
,
Manu Chakravarthy
1
,
Maria P Martinez-Cantarin
3
,
Walter K Kraft
3
Affiliations
1
Merck & Co., Inc., Kenilworth, NJ, USA.
2
Merck & Co., Inc., Kenilworth, NJ, USA. jackie_mccrea@merck.com.
3
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
PMID:
30895461
PMCID:
PMC7018363
DOI:
10.1007/s40261-019-00777-6
Abstract
The original version of this article unfortunately contained a mistake.
Publication types
Published Erratum
Grants and funding
T32 GM008562/GM/NIGMS NIH HHS/United States